" Algernon Pharmaceuticals (CSE:AGN) welcomes new CFO

Algernon Pharmaceuticals (AGN) has appointed Mr. James Kinley as the Chief Financial Officer (CFO), effective December 1, 2021.
The Market Herald Video

" Algernon Pharmaceuticals (CSE:AGN) receives positive feedback from the U.S. FDA for Phase 1 Ifenprodil small cell lung cancer study

Algernon Pharmaceuticals (AGN) has received positive feedback from the U.S. FDA for its investigation of NP-120 (Ifenprodil) to treat small cell lung cancer.
The Market Herald Video

" Algernon Pharmaceuticals (CSE:AGN) establishes optimum treatment period for DMT in neuron study

Algernon Pharmaceuticals (AGN) has established the optimum peak stimulation period for neuron outgrowth by AP-188 (DMT) in its pre-clinical in vitro study.

" Algernon Pharmaceuticals (CSE:AGN) receives $2M payment and applies for Nasdaq listing

Algernon Pharmaceuticals (AGN) has recently received a $2M cash payment from a refundable tax credit program for its clinical research work in Australia.

" Algernon Pharmaceuticals (CSE:AGN) welcomes Dr. Mark Williams to the board

Algernon Pharmaceuticals (AGN) is pleased to announce that Dr. Mark Williams has been appointed as a member of the Board of Directors.

" Algernon Pharmaceuticals (CSE:AGN) welcomes Harry Bloomfield, QC. as a board director and chairman

Algernon Pharmaceuticals (AGN) has elected Harry Bloomfield as a member and Chairman of the Board of Directors.

" Algernon Pharmaceuticals (CSE:AGN) confirms DMT increases neuron growth

Algernon Pharmaceuticals (AGN) has confirmed that DMT increased neuron growth by 40 per cent in a preclinical study.

" Top 5 Stories of the Week: EV Battery Tech (CSE:ACDC), Bluesky Digital Assets (CSE:BTC), Algernon Pharmaceuticals (CSE:AGN), E79 Resources (CSE:ESNR), and Naturally Splendid (TSXV:NSP)

As the Canadian economy continues to bounce back after a disquieting 2020, recessionary measures are making way for a surge in consumer demand.